The Massachusetts biotech industry leads the world in innovation and drug development. But its companies don’t have the support of its own leaders. Why?

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

Biomedical innovators are developing new autoimmune therapeutics - insurance reform will ensure new treatments and cures are accessible and affordable.

An independent and autonomous FDA is a key part of ensuring that the biotech innovation ecosystem can continue to thrive. As an agency, it is the gold standard globally for determining risk-reward benefit in therapies for patients, and the world looks to it to lead the way. The people at the FDA are trying hard to make sure that we actually make progress, and their work is a service to the American public.

America is the global leader in biomedical innovation because it has a market that values new medicines. When other countries pay less, they are free-riding on our willingness to pay for new treatments. Forcing drug manufacturers to charge the same price that these other countries mandate would backfire. Instead, policymakers should use trade negotiations to pressure other wealthy countries to pay their fair share.

Drug development is costly. Who takes the risk and funds the hope of new medicines? Investors do. How do they know which ones will work? They often don't.

At No Patient Left Behind, we believe for insurance to really be insurance it should fully cover the drugs your doctor prescribes when you’re sick–without high out-of-pocket costs.

Who creates new medicines? It takes teams of innovators working with the support of private funding to reach risky new summits and provide patients with new cures.

Medicines help us feel better, but there are so many other things that make medicines valuable. Learn about the many benefits of medicines and the ways that insurers overlook their value to all of us.